The Conversation (0)
NanoSphere Health Sciences (CSE:NSHS), parent company of cannabis brand Evolve Formulas, today announced the latest addition to its cannabis product line-up using NanoSphere Health’s patented delivery technology.
NanoSphere Health Sciences (CSE:NSHS), parent company of cannabis brand Evolve Formulas, today announced the latest addition to its cannabis product line-up using NanoSphere Health’s patented delivery technology. The new Transdermal NanoSerum™ CBD pen is now available with a desirable 10:1 ratio of CBD:THC. The product will be in Colorado dispensaries starting in mid-May.
NanoSphere Health Sciences’ Evolve Formulas NanoSerum
NanoSphere Health’s new Evolve Formulas 5ml NanoSerum™ CBD utilizes a combination formula of CBD and THC, with each precision-metered dose containing 15mg CBD, 1.5mg THC and resveratrol and terpenes for maximum therapeutic benefit. Research supports that CBD can help to relieve inflammation, anxiety, pain, insomnia and mood—making the Evolve CBD pen an excellent option for those suffering a variety of ailments.
Along with naturally-occurring phytocannabinoids and terpenes, the product also contains the restorative ingredient resveratrol. The innovative addition of resveratrol to this pen makes NanoSerum™ CBD a daily solution for antioxidant support, a neuroprotective, a cognitive enhancer and anti-aging promoter.
The NanoSerum™ CBD utilizes the patented NanoSphere Delivery System™, an advanced delivery platform which nano-encapsulates active ingredients in natural, lipid membranes for transportation through five layers of skin and into systemic circulation within minutes for direct delivery to the CB1 and CB2 receptors in the endocannabinoid system throughout the body. This technology eliminates delayed onset of action, vastly increases bioavailability of the ingredients and alleviates adverse side effects.
“The expansion of our product portfolio to include the NanoSerum™ CBD pen allows us to broaden the range of health and wellness benefits we can provide to customers,” said David Sutton, COO and president of NanoSphere Health Sciences and Evolve Formulas. “Our unique combination of CBD, THC and resveratrol offers distinct rejuvenating and anti-aging advantages, as well as antioxidant benefits, to users that aren’t found in other products—and by leveraging the NanoSphere Delivery System™ we also vastly improve how these ingredients deliver their effects safely and reliably.”
Other Evolve Formulas products include the Transdermal NanoSerum™ THC, which is currently available in over 120 dispensaries across Colorado and provides relief from pain, inflammation and anxiety in less than ten minutes by using the NanoSphere Delivery System™. The company has just received the patent for the groundbreaking NanoSphere Delivery System™, giving it ownership over the biggest advancement in non-invasive delivery in over 25 years.
For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 702-957-6203.
On behalf of the Board
David Sutton, President and COO
720.520.4283
dsutton@nanospherehealth.com
Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit https://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.
Source: www.prnewswire.com